{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:33:03Z","timestamp":1781353983746,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Research in Nagoya City University","award":["2213003"],"award-info":[{"award-number":["2213003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The relationship between radiation doses and clinical relapse in patients receiving salvage radiotherapy (SRT) for biochemical recurrence (BCR) after radical prostatectomy (RP) remains unclear. We identified 292 eligible patients treated with SRT between 2005 and 2018 at 15 institutions. Clinical relapse-free survival (cRFS) between the\u2009\u2265\u200966\u00a0Gy (n\u2009=\u2009226) and\u2009&lt;\u200966\u00a0Gy groups (n\u2009=\u200966) were compared using the Log-rank test, followed by univariate and multivariate analyses and a subgroup analysis. After a median follow-up of 73\u00a0months, 6-year biochemical relapse-free survival, cRFS, cancer-specific survival, and overall survival rates were 58, 92, 98, and 94%, respectively. Six-year cRFS rates in the\u2009\u2265\u200966\u00a0Gy and\u2009&lt;\u200966\u00a0Gy groups were 94 and 87%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.022). The multivariate analysis revealed that Gleason score\u2009\u2265\u20098, seminal vesicle involvement, PSA at BCR after RP\u2009\u2265\u20090.5\u00a0ng\/ml, and a dose\u2009&lt;\u200966\u00a0Gy correlated with clinical relapse (<jats:italic>p<\/jats:italic>\u2009=\u20090.015, 0.012, 0.024, and 0.0018, respectively). The subgroup analysis showed the consistent benefit of a dose\u2009\u2265\u200966\u00a0Gy in patients across most subgroups. Doses\u2009\u2265\u200966 Gy were found to  significantly, albeit borderline, increase the risk of late grade\u2009\u2265\u20092 GU toxicity compared to doses\u2009&lt;\u200966 Gy (14% vs. 3.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.055).  This large multi-institutional retrospective study demonstrated that a higher SRT dose (\u2265\u200966\u00a0Gy) resulted in superior cRFS.<\/jats:p>","DOI":"10.1038\/s41598-023-50434-4","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:02:47Z","timestamp":1704196967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy"],"prefix":"10.1038","volume":"14","author":[{"given":"Seiya","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-0119","authenticated-orcid":false,"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Nakanishi-Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Ayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Hiwatashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"50434_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jnci\/djj190","volume":"98","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson, A. J. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. JNCI J. Natl. Cancer Inst. 98, 715\u2013717. https:\/\/doi.org\/10.1093\/jnci\/djj190 (2006).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"50434_CR2","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski, J. M. et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 4, e180039. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0039 (2018).","journal-title":"JAMA Oncol."},{"key":"50434_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2015.01.046","volume":"92","author":"KL Moore","year":"2015","unstructured":"Moore, K. L. et al. Quantifying unnecessary normal tissue complication risks due to suboptimal planning: A secondary study of RTOG 0126. Int. J. Radiat. Oncol. Biol. Phys. 92, 228\u2013235. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.046 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ejca.2011.08.013","volume":"48","author":"N Ohri","year":"2012","unstructured":"Ohri, N., Dicker, A. P., Trabulsi, E. J. & Showalter, T. N. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur. J. Cancer 48, 837\u2013844. https:\/\/doi.org\/10.1016\/j.ejca.2011.08.013 (2012).","journal-title":"Eur. J. Cancer"},{"key":"50434_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","volume":"121","author":"CR King","year":"2016","unstructured":"King, C. R. The dose\u2013response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. Radiother. Oncol. 121, 199\u2013203. https:\/\/doi.org\/10.1016\/j.radonc.2016.10.026 (2016).","journal-title":"Radiother. Oncol."},{"key":"50434_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","volume":"190","author":"IM Thompson","year":"2013","unstructured":"Thompson, I. M. et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO Guideline. J. Urol. 190, 441\u2013449. https:\/\/doi.org\/10.1016\/j.juro.2013.05.032 (2013).","journal-title":"J. Urol."},{"key":"50434_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): prostate cancer, version 1.2023. Sep 16, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (accessed Sep 23, 2022)."},{"key":"50434_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-57056-9","volume":"10","author":"N Tomita","year":"2020","unstructured":"Tomita, N. et al. Impact of advanced radiotherapy techniques and dose intensification on toxicity of salvage radiotherapy after radical prostatectomy. Sci. Rep. 10, 1\u20138. https:\/\/doi.org\/10.1038\/s41598-019-57056-9 (2020).","journal-title":"Sci. Rep."},{"key":"50434_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00432-009-0603-7","volume":"135","author":"N Tomita","year":"2009","unstructured":"Tomita, N. et al. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J. Cancer Res. Clin. Oncol. 135, 1561\u20131567. https:\/\/doi.org\/10.1007\/s00432-009-0603-7 (2009).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"50434_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/ajco.13341","volume":"16","author":"N Tomita","year":"2020","unstructured":"Tomita, N. et al. Early salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: Its impact and optimal candidate. Asia. Pac. J. Clin. Oncol. 16, 273\u2013279. https:\/\/doi.org\/10.1111\/ajco.13341 (2020).","journal-title":"Asia. Pac. J. Clin. Oncol."},{"key":"50434_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler, W. P. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 5, 856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096 (2019).","journal-title":"JAMA Oncol."},{"key":"50434_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler, J. L. et al. Prostate cancer, version 1.2016. J. Natl. Compr. Canc. Netw. 14, 19\u201330. https:\/\/doi.org\/10.6004\/jnccn.2016.0004 (2016).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"50434_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042 (2021).","journal-title":"Eur. Urol."},{"key":"50434_CR14","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25, 2035\u20132041. https:\/\/doi.org\/10.1200\/JCO.2006.08.9607 (2007).","journal-title":"J. Clin. Oncol."},{"key":"50434_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417\u2013428. https:\/\/doi.org\/10.1056\/NEJMoa1607529 (2017).","journal-title":"N. Engl. J. Med."},{"key":"50434_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1200\/JCO.2006.09.6495","volume":"25","author":"GP Swanson","year":"2007","unstructured":"Swanson, G. P. et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J. Clin. Oncol. 25, 2225\u20132229. https:\/\/doi.org\/10.1200\/JCO.2006.09.6495 (2007).","journal-title":"J. Clin. Oncol."},{"key":"50434_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ijrobp.2016.08.043","volume":"96","author":"TM Pisansky","year":"2016","unstructured":"Pisansky, T. M. et al. Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy\u2014A multi-institutional observational study. Int. J. Radiat. Oncol. Biol. Phys. 96, 1046\u20131053. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.043 (2016).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.02.049","volume":"76","author":"JR Bernard","year":"2010","unstructured":"Bernard, J. R. et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: Dose-response analysis. Int. J. Radiat. Oncol. Biol. Phys. 76, 735\u2013740. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.049 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.radonc.2008.05.006","volume":"88","author":"MA Sidhom","year":"2008","unstructured":"Sidhom, M. A. et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother. Oncol. 88, 10\u201319. https:\/\/doi.org\/10.1016\/j.radonc.2008.05.006 (2008).","journal-title":"Radiother. Oncol."},{"key":"50434_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"50434_CR21","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar, R. D. et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J. Clin. Oncol. 34, 3648\u20133654. https:\/\/doi.org\/10.1200\/JCO.2016.67.9647 (2016).","journal-title":"J. Clin. Oncol."},{"key":"50434_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2011.10.077","volume":"84","author":"A Goenka","year":"2012","unstructured":"Goenka, A. et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int. J. Radiat. Oncol. Biol. Phys. 84, 112\u2013118. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.10.077 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","volume":"80","author":"P Ghadjar","year":"2021","unstructured":"Ghadjar, P. et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: The SAKK 09\/10 randomized phase 3 trial. Eur. Urol. 80, 306\u2013315. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.033 (2021).","journal-title":"Eur. Urol."},{"key":"50434_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","volume":"106","author":"X Qi","year":"2020","unstructured":"Qi, X. et al. Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 106, 282\u2013290. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.047 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/cancers14051320","volume":"14","author":"D B\u00f6hmer","year":"2022","unstructured":"B\u00f6hmer, D. et al. Impact of dose escalation on the efficacy of salvage radiotherapy for recurrent prostate cancer\u2014A risk-adjusted, matched-pair analysis. Cancers Basel. 14, 1320. https:\/\/doi.org\/10.3390\/cancers14051320 (2022).","journal-title":"Cancers Basel."},{"key":"50434_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.eururo.2017.07.026","volume":"73","author":"N Fossati","year":"2018","unstructured":"Fossati, N. et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur. Urol. 73, 436\u2013444. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.026 (2018).","journal-title":"Eur. Urol."},{"key":"50434_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","volume":"296","author":"IM Thompson","year":"2006","unstructured":"Thompson, I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329\u20132335. https:\/\/doi.org\/10.1001\/jama.296.19.2329 (2006).","journal-title":"JAMA"},{"key":"50434_CR28","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","volume":"34","author":"BJ Stish","year":"2016","unstructured":"Stish, B. J. et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J. Clin. Oncol. 34, 3864\u20133871. https:\/\/doi.org\/10.1200\/JCO.2016.68.3425 (2016).","journal-title":"J. Clin. Oncol."},{"key":"50434_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bju.13792","volume":"120","author":"WC Jackson","year":"2017","unstructured":"Jackson, W. C. et al. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 120, 351\u2013357. https:\/\/doi.org\/10.1111\/bju.13792 (2017).","journal-title":"BJU Int."},{"key":"50434_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0360-3016(00)00637-4","volume":"48","author":"J Crook","year":"2000","unstructured":"Crook, J. et al. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys. 48, 355\u2013367. https:\/\/doi.org\/10.1016\/S0360-3016(00)00637-4 (2000).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR31","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack, A. et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399, 1886\u20131901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6 (2022).","journal-title":"Lancet"},{"key":"50434_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","volume":"17","author":"C Carrie","year":"2016","unstructured":"Carrie, C. et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 17, 747\u2013756. https:\/\/doi.org\/10.1016\/S1470-2045(16)00111-X (2016).","journal-title":"Lancet Oncol."},{"key":"50434_CR33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.ijrobp.2007.01.049","volume":"68","author":"M Feng","year":"2007","unstructured":"Feng, M. et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 68, 1417\u20131423. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.01.049 (2007).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2009.08.023","volume":"78","author":"SK Nath","year":"2010","unstructured":"Nath, S. K. et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78, 435\u2013441. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.023 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"50434_CR35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"P Marlon","year":"2016","unstructured":"Marlon, P. et al. Sensitivity, specificity, and predictors of positive 68Ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur. Urol. 70, 926\u2013937. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.021 (2016).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50434-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T12:11:46Z","timestamp":1704197506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50434-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50434"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50434-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}